How Disbrow was paid
$883,928 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Total |
|---|---|---|---|---|---|
| Joshua R. DisbrowChief Executive Officer since April 2015 | $590,000 | — | $46,128 | $247,800 | $883,928 |
| Ryan J. SelhornChief Financial Officer, Corporate Secretary and Treasurer since November 2024 | $379,796 | $24,780 | $6,070 | $128,000 | $538,646 |
| Mark K. OkiFormer Chief Financial Officer, Corporate Secretary and Treasurer | $238,387 | — | — | — | $238,387 |
| Jarrett T. DisbrowChief Business Officer since November 2022 | $386,250 | — | $8,497 | $154,500 | $549,247 |
| Greg PyszczymukaChief Commercial Officer since January 2022 | $401,403 | — | $8,497 | $112,176 | $522,076 |
What changed and why
- $884K$883,928 was CEO total compensation in 2025, compared with $928,217 in 2024.
- $248K$247,800 was the CEO’s 2025 non-equity incentive compensation tied to corporate objectives.
- $46,128$46,128 was the CEO’s 2025 option award value.
- $539K$538,646 was CFO Ryan J. Selhorn’s total compensation after his November 2024 appointment.
- 14,000 restricted shares were granted to Ryan J. Selhorn under his employment agreement.
- 40%40% of base salary was Ryan J. Selhorn’s target annual bonus.
Other AYTU Biopharma proxy statements
- 2026 proxy statement
Joshua R. Disbrow paid $844,854 (-4% on the year).
Filed Oct 22, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.